P/E at 25.34 vs Industry's 33.41: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of 25.34 for Dr Reddys Laboratories Ltd stands well below the sector average of 33.41, indicating a valuation discount of nearly 24%. This gap suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or a risk premium relative to its peers. The Pharmaceuticals & Biotechnology sector often commands elevated multiples due to growth expectations and innovation potential, but Dr Reddys Laboratories Ltd appears to be trading on a more conservative valuation basis. What factors are driving this valuation gap despite the company’s large-cap status?

Performance Across Timeframes: Mixed Momentum Signals

Examining the stock’s returns reveals a nuanced performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 5.40%, which, while negative, is a relative outperformance compared to the Sensex’s 10.80% fall. This suggests some resilience in the longer term. However, the three-month return of -3.61% is more pronounced, and the one-month return is slightly negative at -0.16%, indicating recent softness. In contrast, the stock has shown modest gains in the short term, with a 1-day gain of 0.46% and a 1-week increase of 0.83%, both outperforming the Sensex’s negative returns in those periods. This divergence between short-term strength and medium-term weakness raises questions about the sustainability of recent gains — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Signs of a Partial Recovery

The technical setup for Dr Reddys Laboratories Ltd is revealing. The stock currently trades above its 200-day moving average, a long-term bullish indicator, but remains below its 5-day, 20-day, 50-day, and 100-day moving averages. This configuration suggests that while the stock has maintained a base above the longest-term average, it is still facing resistance in the short to medium term. Such a pattern often indicates a recovery attempt within a broader downtrend or consolidation phase. The 200 DMA support may provide a floor, but the inability to break above shorter-term averages points to ongoing caution among investors. Is this a technical pause before a sustained uptrend or a dead-cat bounce?

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 35 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 7 posted negative results. This distribution indicates a broadly stable sector with pockets of strength and weakness. Dr Reddys Laboratories Ltd’s relative valuation discount may reflect cautious sentiment amid this uneven sector backdrop. The company’s large-cap status and market cap of ₹1,06,637.32 crores position it as a key player, but the sector’s mixed earnings performance could be tempering enthusiasm.

Rating Context: Previously Rated Buy, Now Reassessed

Dr Reddys Laboratories Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 51.0 and a Hold grade prior to the reassessment on 4 May 2026. The updated rating reflects a recalibration based on the latest valuation, performance, and technical data. The stock’s current trading multiples and mixed momentum profile suggest a more cautious stance. What is the current rating for Dr Reddys Laboratories Ltd given these developments?

Longer-Term Performance: Outperformance and Underperformance

Looking beyond the recent year, Dr Reddys Laboratories Ltd has delivered a 36.80% return over three years, comfortably outperforming the Sensex’s 17.53% gain. However, over five years, the stock’s 17.19% return trails the Sensex’s 40.26%, and over ten years, the stock’s 108.44% gain is below the Sensex’s 176.33%. This mixed long-term performance profile highlights periods of both strength and relative weakness, underscoring the importance of timeframe when analysing the stock’s trajectory. The recent valuation discount may partly reflect this uneven longer-term record.

Intraday and Short-Term Performance: Slight Outperformance

On 11 June 2026, Dr Reddys Laboratories Ltd recorded a 0.46% gain, outperforming the Pharmaceuticals & Biotechnology sector by 0.28%. The stock opened and traded at ₹1265.25, maintaining stability throughout the session. This short-term outperformance contrasts with the broader sector’s mixed results and the Sensex’s negative intraday movement of -0.52%. Such resilience in daily and weekly timeframes may indicate underlying support, but the broader medium-term weakness remains a concern for investors. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Collective Data Insights: A Complex Picture

The data for Dr Reddys Laboratories Ltd paints a multifaceted picture. The valuation discount relative to the sector’s P/E ratio suggests cautious market sentiment despite the company’s large-cap stature. Performance metrics reveal resilience over one year and three years but recent softness over three months and one month. The moving average configuration points to a tentative recovery above the 200-day average but resistance at shorter-term averages. Sector results are mixed, and the rating reassessment from Buy to Hold reflects these complexities. Taken together, the data highlights the importance of timeframe and valuation context in analysing this stock’s current standing.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →